

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/002508-2026>

Planning

## **NHS NOFE and Midlands & East Branded Medicines - Tranche A- 1 September 2026**

NHS England

UK2: Preliminary market engagement notice - Procurement Act 2023 - [view information about notice types](#)

Notice identifier: 2026/S 000-002508

Procurement identifier (OCID): ocds-h6vhtk-051c98 ([view related notices](#))

Published 13 January 2026, 9:57am

### **Scope**

### **Reference**

C414060

### **Description**

NHS Branded Framework Agreement – Lot 1 - Tranche A for the North of England and Midlands & East.

Period of Framework Agreement: 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority's discretion for a further 24 months).

Lot 2 - Natalizumab for London and South of England. The period of Framework Agreement : 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.

## **Commercial tool**

Establishes a framework

## **Total value (estimated)**

- £456,000,000 excluding VAT
- £547,200,000 including VAT

Above the relevant threshold

## **Contract dates (estimated)**

- 1 September 2026 to 31 August 2028
- Possible extension to 31 August 2030
- 4 years

## **Main procurement category**

Goods

## **CPV classifications**

- 33600000 - Pharmaceutical products

## **Contract locations**

- UKC - North East (England)
- UKD - North West (England)
- UKF - East Midlands (England)

- UKG - West Midlands (England)
- UKH - East of England
- UKI - London
- UKK - South West (England)
- UKJ - South East (England)

---

## Engagement

### Engagement deadline

27 January 2026

### Engagement process description

NHS England is advising suppliers of an upcoming tender for the NHS Branded Framework Agreement – Tranche A for the North of England and Midlands & East.

Period of Framework Agreement (Lot 1): 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority's discretion for a further 24 months).

There will be a separate Lot to provide framework agreement coverage to the London and South of England regions for Natalizumab. The period of Framework Agreement (Lot 2): 1st September 2026 to 31st August 2027 with the option or option(s) to extend for a further 12 months.

Eight category areas are covered in Tranche A: Erythropoietin Stimulating Agents, Granulocyte-Colony Stimulating Factor (GCSF), Insulin Analogues, MS Drugs, Parenteral Iron, Severe Asthma, Severe Asthma/Interleukin Inhibitor and Teriparatide.

The purpose of this notice is to inform existing and potential new suppliers that if NHS England believe that it would be beneficial a virtual 1:1 preliminary market meeting can be arranged. Please contact [ian.birch1@nhs.net](mailto:ian.birch1@nhs.net) to register your interest. There will also be a 14 day window for queries to be raised via Atamis after all sessions have concluded.

---

## **Participation**

### **Particular suitability**

Small and medium-sized enterprises (SME)

---

## **Submission**

### **Publication date of tender notice (estimated)**

9 March 2026

---

## **Contracting authority**

### **NHS England**

- Public Procurement Organisation Number: PDPT-3135-BWWY

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

United Kingdom

Email: [lynne.tierney@nhs.net](mailto:lynne.tierney@nhs.net)

Website: <https://www.england.nhs.uk/>

Region: UKI45 - Lambeth

Organisation type: Public authority - central government